FiercePharma13h
JPM25, Day 3: AbbVie's 'clear runway to growth' allows it to focus on early-stage acquisitions
Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...
FiercePharma8h
JPM25: Bayer gears up for 'must-win battles' as Xarelto loss of exclusivity in full swing, says pharma chief
These launches belong to what Oelrich called “must-win battles” at Bayer as Xarelto loss of exclusivity reaches “full swing” ...
FiercePharma12h
JPM25: Takeda spotlights 6 pipeline assets that could pull down up to $20B in collective peak sales
Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...
FiercePharma12h
Lyndra taps Thermo Fisher to help with research, commercial production of long-acting oral meds
As Lyndra Therapeutics works to advance long-acting oral drugs for a range of diseases, the Massachusetts-based biotech is ...
FiercePharma18h
JPM25: Amid Samsung Bio's rapid expansion, CDMO weighs plan to build a 6th plant
“Despite industry challenges, Samsung Biologics is well positioned to kick-start a new phase of growth in 2025 with the ...
FiercePharma8h
JPM25: Emergent secures licensing deal for opioid overdose spray amid recovery plan
After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it attempts to reestablish its unique role as a drug developer combating u | ...